证券代码：688073 证券简称：毕得医药 公告编号：2025-070 上海毕得医药科技股份有限公司 关于公司董事辞职暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海毕得医药科技股份有限公司（以下简称"公司"）董事会近日收到赵芸 女士、张锐豪先生提交的书面辞职报告。因公司内部工作调整，赵芸女士辞去公 司董事及审计委员会委员、薪酬与考核委员会委员职务，张锐豪先生辞去公司董 事及战略委员会委员职务，辞任后，赵芸女士、张锐豪先生仍然担任公司其他职 务。公司于 2025 年 8 月 8 日召开职工代表大会，经全体与会职工代表表决，同 意选举尚卓婷女士、许丽姣女士担任公司第二届董事会职工代表董事。 一、董事离任情况 根据《公司法》《上海证券交易所科创板股票上市规则》等法律法规以及《公 司章程》的相关规定，公司于 2025 年 8 月 8 日召开职工代表大会，经与会代表 认真审议并投票表决，同意选取尚卓婷女士、许丽姣女士为公司第二届董事会职 工代表董事。公司对选举结果进行了公示，2025 年 8 ...

Core Points - The Shanghai Composite Index closed at 3638.40 points with a change of 0.12% and a total trading volume of 1,206.179 billion yuan [1] - Eight A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stock Performance - Stock "信立泰" (Code: 002294) decreased by 1.86% with a 5-day moving average of 49.37 yuan and a 10-day moving average of 49.62 yuan, showing a distance of -0.49% [1] - Stock "万邦德" (Code: 002082) decreased by 1.36% with a 5-day moving average of 7.48 yuan and a 10-day moving average of 7.52 yuan, also showing a distance of -0.49% [1] - Stock "毕得医药" (Code: 688073) decreased by 2.96% with a 5-day moving average of 59.09 yuan and a 10-day moving average of 59.27 yuan, indicating a distance of -0.30% [1] Group 2: Additional Stocks with Moving Average Crossovers - Stock "吉贝尔" (Code: 688566) decreased by 3.58% with a 5-day moving average of 33.90 yuan and a 10-day moving average of 33.97 yuan, showing a distance of -0.20% [1] - Stock "诺诚健华" (Code: 688428) decreased by 6.03% with a 5-day moving average of 30.02 yuan and a 10-day moving average of 30.07 yuan, indicating a distance of -0.18% [1] - Stock "丽人丽妆" (Code: 605136) increased by 0.81% with a 5-day moving average of 9.82 yuan and a 10-day moving average of 9.84 yuan, showing a distance of -0.15% [1]

毕得医药属于生物制品行业，公司主营业务涵盖医药研发服务领域。作为上海板块上市公司，公司具有 专精特新企业资质，并涉及CRO业务领域。 截至2025年8月6日收盘，毕得医药股价报58.79元，较前一交易日下跌1.78元，跌幅为2.94%。当日开盘 价为61.50元，最高触及61.95元，最低下探至58.60元，成交量为14360手，成交金额达0.86亿元。 风险提示：以上内容仅供参考，不构成投资建议。股市有风险，投资需谨慎。 从资金流向来看，8月6日主力资金净流出536.35万元，占流通市值的0.21%。近五个交易日累计净流出 1124.51万元，占流通市值的0.44%。 ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-069 上海毕得医药科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/2/8，由董事长提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 2 8 | 24 | 日~2025 | 年 | 月 | 日 23 | | 预计回购金额 | 5,000万元~10,000万元 | | | | | | | 回购价格上限 | 71.44元/股 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 实际回购股数 | 2,176,148股 | | | | | | | 实际回购股数占总股本比例 | 2.39% | | | | | | ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-068 上海毕得医药科技股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 31 日 （二） 股东大会召开的地点：上海市杨浦区翔殷路 999 号 3 幢 6 层会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 37 | | --- | --- | | 普通股股东人数 | 37 | | 2、出席会议的股东所持有的表决权数量 | 52,570,712 | | 普通股股东所持有表决权数量 | 52,570,712 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 61.0203 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 61.0203 | （ ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于上海毕得医药科技股份有限公司 2025 年第四次临时股东大会的 法律意见书 国枫律股字[2025] A0378 号 致：上海毕得医药科技股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2025 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《上 海毕得医药科技股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 ...

Group 1 - The core stock price of Bid Pharma on July 30 was 59.06 yuan, down by 2.42 yuan, representing a decline of 3.94% [1] - The trading volume on the same day was 100 million yuan, with a turnover rate of 3.84%, and the total market capitalization stood at 5.368 billion yuan [1] - Bid Pharma specializes in the biopharmaceutical sector, focusing on pharmaceutical research and development services, and operates within the bioproducts and CRO industry segments [1] Group 2 - The company will hold its fourth extraordinary general meeting of shareholders for 2025 on July 31 to discuss multiple proposals, including changes to its business scope, the cancellation of the supervisory board, and amendments to the company’s articles of association [1] - The meeting will take place at the conference room on the 6th floor of Building 3, No. 999 Xiangyin Road, Yangpu District, Shanghai [1] - On July 30, the net outflow of main funds was 15.3766 million yuan, accounting for 0.6% of the circulating market value [1]

Company Overview - Bid Pharma, established in 2007 and headquartered in Shanghai, focuses on the research, production, sales, and custom synthesis of pharmaceutical intermediates [1] Stock Performance - Bid Pharma has experienced a decline in stock price for five consecutive trading days, with a cumulative drop of -3.54% [1] Fund Holdings - China Europe Fund's China Europe Medical Health Mixed A is among the top ten shareholders of Bid Pharma, maintaining its position in the second quarter of this year [2] - The fund has achieved a year-to-date return of 19.65%, ranking 909 out of 4513 in its category [2] Fund Performance Comparison - The performance of China Europe Medical Health Mixed A fund shows a year-to-date increase of 19.65%, compared to the category average of 13.49% and the CSI 300 index's 5.44% [3] Fund Manager Profiles - The fund is managed by Guo Lan, who has a Ph.D. in Biomedical Engineering from Northwestern University and has been with China Europe Fund since October 2014 [4][5] - Zhao Lei, who has a master's degree and previously worked as a researcher in the pharmaceutical and biotechnology sector, joined China Europe Fund in May 2021 and became a fund manager on July 4, 2025 [6] Fund Management Details - Guo Lan has managed multiple funds and has a total fund size of 399.08 billion with a return of 106.72% [5] - Zhao Lei currently manages two funds with a total size of 308.01 billion, achieving a return of 8.02% since her appointment [6] Company Structure - China Europe Fund Management Company was established in July 2006 and has 25 shareholders, with WP Asia Pacific Asset Management LLC holding 23.30% [6]

Group 1: Bid Medicine - Bid Medicine emphasizes capital operations and resource integration as key strategic focuses for future development, aiming to expand global business through various means and continuously seek acquisition opportunities [1] - The company has completed its global market layout, established multiple regional centers, and upgraded its U.S. warehouse and R&D center, resulting in rapid growth in overseas business [1] - Bid Medicine is facing a 20% fentanyl tax and a small 10% equivalent tariff on products sold in the U.S., but it has managed to pass on costs through price increases and discount adjustments, leading to minimal impact [1] - The company perceives a gradual recovery in industry demand, with improving orders from overseas and ongoing stimulation of market growth due to domestic innovative drug policies [1] Group 2: Medicy - Medicy is strengthening key technology research for hot drug development and building multiple innovative technology service platforms covering CGT, nucleic acid drugs, and PROTC [2] - The company has taken measures to ensure stable supply of experimental monkeys and has established a research laboratory in Boston, enhancing its overseas market expansion [2] - Medicy is focusing on talent development, optimizing internal organization and talent structure, and aims to improve operational conditions through cost reduction, efficiency enhancement, and strengthened R&D capabilities [2] - The domestic CRO industry is expected to benefit from policy support and the advancement of innovative drug development [2]

上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议资料 证券代码：688073 证券简称：毕得医药 上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议资料 2025 年 7 月 | 2025 年第四次临时股东大会会议须知 | 1 | | --- | --- | | 2025 年第四次临时股东大会会议议程 | 4 | | 2025 年第四次临时股东大会会议议案 | 6 | | 案 6 | | | 议案二：关于修改公司部分内部制度的议案 8 | | | 议案三：关于续聘公司 2025 年度审计机构的议案 10 | | 上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议资料 上海毕得医药科技股份有限公司 2025 年第四次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证 大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东大会规则》以及《上海毕得医药科技股份有限公司章程》等相关规定， 上海毕得医药科技股份有限公司（以下简称"公司"或"毕得医药"）特制定股 东大会会议须知： 一、为确认出席大会的股东或其代 ...